Phase I Study of TheraSphere and Everolimus Among Patients With Neuroendocrine Tumors and Liver Only or Liver Dominant Disease

Trial Profile

Phase I Study of TheraSphere and Everolimus Among Patients With Neuroendocrine Tumors and Liver Only or Liver Dominant Disease

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2014

At a glance

  • Drugs Everolimus (Primary)
  • Indications Liver metastases; Neuroendocrine carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 28 Jan 2014 Planned initiation date changed from 1 Nov 2013 to 1 May 2014 as reported by ClinicalTrials.gov record.
    • 28 Jan 2014 Planned End Date changed from 1 Nov 2017 to 1 May 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top